HOXB13 is downregulated in colorectal cancer to confer TCF4-mediated transactivation
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Mutations in the Wnt signalling cascade are believed to cause aberrant proliferation of colorectal cells through T-cell factor-4 (TCF4) and its downstream growth-modulating factors. HOXB13 is exclusively expressed in prostate and colorectum. In prostate cancers, HOXB13 negatively regulates beta-catenin/TCF4-mediated transactivation and subsequently inhibits cell growth. To study the role of HOXB13 in colorectal tumorigenesis, we evaluated the expression of HOXB13 in 53 colorectal tumours originated from the distal left colon to rectum with their matching normal tissues using quantitative RT-PCR analysis. Expression of HOXB13 is either lost or diminished in 26 out of 42 valid tumours (62%), while expression of TCF4 RNA is not correlated with HOXB13 expression. TCF4 promoter analysis showed that HOXB13 does not regulate TCF4 at the transcriptional level. However, HOXB13 downregulated the expression of TCF4 and its target gene, c-myc, at the protein level and consequently inhibited beta-catenin/TCF-mediated signalling. Functionally, forced expression of HOXB13 drove colorectal cancer (CRC) cells into growth suppression. This is the first description of the downregulation of HOXB13 in CRC and its mechanism of action is mediated through the regulation of TCF4 protein stability. Our results suggest that loss of HOXB13 may be an important event for colorectal cell transformation, considering that over 90% of colorectal tumours retain mutations in the APC/beta-catenin pathway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Tiwari, R. C., Murray, T., Ghafoor, A., Samuels, A., Ward, E., Feuer, E. J., & Thun, M. J. (2004) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.54.1.8 · Cited by 3,984
β-Catenin regulates expression of cyclin D1 in colon carcinoma cells
Tetsu, O., & McCormick, F. (1999) · Nature · doi:10.1038/18884 · Cited by 3,601
Polakis, P. (2000) · Genes & Development · doi:10.1101/gad.14.15.1837 · Cited by 3,183
Systems Biology and New Technologies Enable Predictive and Preventative Medicine
Hood, L., Heath, J. R., Phelps, M. E., & Lin, B. (2004) · Science · doi:10.1126/science.1104635 · Cited by 1,108 · cited 1×
“Tissue-specific expression of HOXB13 is also well reported in human (Aarnisalo et al, 1998; Edwards et al, 2005; Hood et al, 2004; Jung et al, 2004b; Takahashi et al, 2004).”
BackgroundCREB-binding protein in androgen receptor-mediated signaling
Aarnisalo, P., Palvimo, J. J., & Jänne, O. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.5.2122 · Cited by 255
Song, L.-N., Herrell, R., Byers, S., Shah, S., Wilson, E. M., & Gelmann, E. P. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.5.1674-1687.2003 · Cited by 169
Ligand-dependent inhibition of β-catenin/TCF signaling by androgen receptor
Chesire, D. R., & Isaacs, W. B. (2002) · Oncogene · doi:10.1038/sj.onc.1206049 · Cited by 151 · cited 1×
“In addition, up to 38% of metastatic androgenindependent prostate tumours have abnormal accumulation of b-catenin (Chesire and Isaacs, 2002; de la Taille et al, 2003).”
BackgroundHoxb13 knockout adult skin exhibits high levels of hyaluronan and enhanced wound healing
Mack, J. A., Abramson, S. R., Ben, Y., Coffin, J. C., Rothrock, J. K., Maytin, E. V., Hascall, V. C., Largman, C., & Stelnicki, E. J. (2003) · The FASEB Journal · doi:10.1096/fj.02-0959fje · Cited by 80 · cited 2×
“Most noticeably, HOXB13 decreased CRT activity up to 12-fold in HCT116 cells, in which b-catenin has a deletion of Ser45 inhibiting the downregulation of b-catenin through phosphorylation.”
Background
Cited by
The Hox genes and their roles in oncogenesis
Shah, N., & Sukumar, S. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2826 · Cited by 835
Wnt/β-catenin signaling in cancers and targeted therapies
Yu, F., Yu, C., Li, F., Zuo, Y., Wang, Y., Yao, L., Wu, C., Wang, C., & Ye, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00701-5 · Cited by 734
“Specifically, HOXB13 expression was downregulated in colorectal and prostate cancer.(240,241) And it inhibited the growth of cancers by reducing Tcf and c-myc protein levels.”
BackgroundThe regulation of β-catenin activity and function in cancer: therapeutic opportunities
Shang, S., Hua, F., & Hu, Z.-W. (2017) · Oncotarget · doi:10.18632/oncotarget.15687 · Cited by 641
The c‐myc Promoter: Still MysterY and Challenge
(2008) · Advances in Cancer Research · doi:10.1016/s0065-230x(07)99004-1 · Cited by 211
The dual roles of homeobox genes in vascularization and wound healing
Kachgal, S., Mace, K. A., & Boudreau, N. J. (2012) · Cell Adhesion & Migration · doi:10.4161/cam.22164 · Cited by 72
Metadata
- Authors
- Jung, C., Kim, R.-S., Zhang, H., Lee, S.-J., Sheng, H., Loehrer, P. J., Gardner, T. A., Jeng, M.-H., & Kao, C.
- Venue
- British Journal of Cancer
- Published
- 2005-05-31
- Volume
- 92
- Issue
- 12
- Pages
- 2233-2239
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W1978587044
- Cited by
- 104
- References
- 8
- FWCI
- 0.92
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: HOXB13 is downregulated in colorectal cancer to confer TCF4-mediated transactivation. https://app.cochat.ai/papers/10.1038/sj.bjc.6602631
- The paper
- Jung, C., Kim, R.-S., Zhang, H., Lee, S.-J., Sheng, H., Loehrer, P. J., Gardner, T. A., Jeng, M.-H., & Kao, C. (2005). HOXB13 is downregulated in colorectal cancer to confer TCF4-mediated transactivation. British Journal of Cancer. https://doi.org/10.1038/sj.bjc.6602631
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.